All Publications


  • Improving Scientific Judgments in Law and Government: A Field Experiment of Patent Peer Review JOURNAL OF EMPIRICAL LEGAL STUDIES Ho, D. E., Ouellette, L. 2020; 17 (2): 190–223

    View details for DOI 10.1111/jels.12249

    View details for Web of Science ID 000534645700001

  • THE MEDICARE INNOVATION SUBSIDY NEW YORK UNIVERSITY LAW REVIEW Lemley, M. A., Ouellette, L., Sachs, R. E. 2020; 95 (1): 75–129
  • How do patent incentives affect university researchers? INTERNATIONAL REVIEW OF LAW AND ECONOMICS Ouellette, L., Tutt, A. 2020; 61
  • Innovation policy and the market for vaccines. Journal of law and the biosciences Xue, Q. C., Ouellette, L. L. 2020; 7 (1): lsaa026

    Abstract

    Vaccines play a crucial role in improving global public health, with the ability to stem the spread of infectious diseases and the potential to eradicate them completely. Compared with pharmaceuticals that treat disease, however, preventative vaccines have received less attention from both biomedical researchers and innovation scholars. This neglect has substantial human and financial costs, as vividly illustrated by the COVID-19 pandemic. In this article, we argue that the large number of ``missing'' vaccines is likely due to more than lack of scientific opportunities. Two key aspects of vaccines help account for their anemic development pipeline: (1) they are preventatives rather than treatments; and (2) they are generally durable goods with long-term effects rather than products purchased repeatedly. We explain how both aspects make vaccines less profitable than repeat-purchase treatments, even given comparable IP protection. We conclude by arguing that innovation policy should address these market distortions by experimenting with larger government-set rewards for vaccine production and use. Most modestly, policymakers should increase direct funding-including no grants and public-private partnerships-and insurance-based market subsidies for vaccine development. We also make the case for a large cash prize for any new vaccine made available at low or zero cost.

    View details for DOI 10.1093/jlb/lsaa026

    View details for PubMedID 32733687

    View details for PubMedCentralID PMC7381976

  • Science fiction: Fictitious experiments in patents. Science (New York, N.Y.) Freilich, J. n., Ouellette, L. L. 2019; 364 (6445): 1036–37

    View details for DOI 10.1126/science.aax0748

    View details for PubMedID 31197002

  • Innovation Policy Pluralism YALE LAW JOURNAL Hemel, D. J., Ouellette, L. 2019; 128 (3): 544–614
  • Selling Patents to Indian Tribes to Delay the Market Entry of Generic Drugs JAMA INTERNAL MEDICINE Ablavsky, G., Ouellette, L. 2018; 178 (2): 179–80
  • PUBLIC PERCEPTIONS OF GOVERNMENT SPEECH SUPREME COURT REVIEW 2017 Hemel, D. J., Ouellette, L., Hutchinson, D. J., Strauss, D. A., Stone, G. R. 2018: 33–92
  • Bayh-Dole beyond borders JOURNAL OF LAW AND THE BIOSCIENCES Hemel, D. J., Ouellette, L. 2017; 4 (2): 282–310

    View details for DOI 10.1093/jlb/lsx011

    View details for Web of Science ID 000417361000003

  • A MARKET TEST FOR BAYH-DOLE PATENTS CORNELL LAW REVIEW Ayres, I., Ouellette, L. L. 2017; 102 (2): 271-334
  • Who reads patents? Nature biotechnology Ouellette, L. L. 2017; 35 (5): 421–24

    View details for PubMedID 28486445

  • Knowledge Goods and Nation-States MINNESOTA LAW REVIEW Hemel, D. J., Ouellette, L. L. 2017; 101 (1): 167-243
  • Pierson, Peer Review, and Patent Law VANDERBILT LAW REVIEW Ouellette, L. L. 2016; 69 (6): 1825-1848
  • HOW COURTS ADJUDICATE PATENT DEFINITENESS AND DISCLOSURE DUKE LAW JOURNAL Allison, J. R., Ouellette, L. L. 2016; 65 (4): 609-695
  • Deference Mistakes UNIVERSITY OF CHICAGO LAW REVIEW Masur, J. S., Ouellette, L. L. 2015; 82 (2): 643-731
  • PATENT EXPERIMENTALISM VIRGINIA LAW REVIEW Ouellette, L. L. 2015; 101 (1): 65-128